Key result
Review highlights persistent underrepresentation of geriatric patients in clinical trials despite high medication use.
Why the study?
Patients aged 65 and older receive about 60% of prescribed medicines yet remain underrepresented in clinical trials.
Answers are grounded in this paper and cite their sources.
Highlights the underrepresentation of the geriatric population in clinical trials and summarizes international regulatory guidelines to address this issue.
The number of old and very old people is increasing every year. Geriatric population is considered as the most growing age group. By different estimations about 60% of medicines are prescribed to patients of 65 and older. In the same time this age group is underrepresented in clinical trials. Participation of elderlies in clinical trials is really actual now and requires further development form regulatory authorities, drug manufactures and investigators. This review summarizes actual international guidelines on clinical trials in geriatric population.
No takes yet. Share an insight, caveat, or question.
I. P. Malaya (2021) conducted a review in Geriatrics. This review summarizes current international guidelines on clinical trials in the geriatric population, highlighting the underrepresentation of patients aged 65 and older despite high medication use.
Synapse has enriched 10 related papers. Consider them for comparative context: